MIM
NBIX icon

MetLife Investment Management’s Neurocrine Biosciences NBIX Stock Holding History

MetLife Investment Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.72M Sell
51,732
-1,321
-2% -$196K 0.04% 417
2026
Q1 		$6.99M Buy
53,053
+387
+0.7% +$51.3K 0.04% 479
2025
Q4 		$7.47M Sell
52,666
-2,195
-4% -$318K 0.04% 453
2025
Q3 		$7.7M Sell
54,861
-2,166
-4% -$293K 0.04% 449
2025
Q2 		$7.17M Sell
57,027
-2,680
-4% -$307K 0.04% 427
2025
Q1 		$6.6M Sell
59,707
-1,735
-3% -$220K 0.04% 488
2024
Q4 		$8.39M Buy
61,442
+4,735
+8% +$586K 0.05% 320
2024
Q3 		$6.53M Sell
56,707
-895
-2% -$123K 0.04% 397
2024
Q2 		$7.93M Sell
57,602
-1,002
-2% -$137K 0.05% 302
2024
Q1 		$8.08M Sell
58,604
-744
-1% -$102K 0.05% 290
2023
Q4 		$7.82M Sell
59,348
-620
-1% -$71.4K 0.06% 285
2023
Q3 		$6.75M Sell
59,968
-2,512
-4% -$265K 0.05% 303
2023
Q2 		$5.89M Sell
62,480
-552
-0.9% -$53.9K 0.04% 366
2023
Q1 		$6.38M Sell
63,032
-1,238
-2% -$129K 0.05% 334
2022
Q4 		$7.68M Sell
64,270
-1,065
-2% -$125K 0.06% 273
2022
Q3 		$6.94M Sell
65,335
-683
-1% -$69.3K 0.06% 279
2022
Q2 		$6.44M Buy
66,018
+509
+0.8% +$47K 0.05% 311
2022
Q1 		$6.14M Buy
65,509
+19,535
+42% +$1.66M 0.04% 401
2021
Q4 		$3.92M Buy
45,974
+505
+1% +$46.5K 0.03% 527
2021
Q3 		$4.36M Sell
45,469
-1,773
-4% -$167K 0.04% 441
2021
Q2 		$4.6M Sell
47,242
-1,284
-3% -$123K 0.04% 433
2021
Q1 		$4.72M Buy
+48,526
New +$5.09M 0.04% 422
2019
Q2 		– Sell
-369
Closed -$32.7K – 2546
2019
Q1 		$32.7K Buy
369
+247
+202% +$20.6K ﹤0.01% 2390
2018
Q4 		$8.71K Sell
122
-1
-0.8% -$96 ﹤0.01% 2394
2018
Q3 		$15.1K Buy
+123
New +$14K ﹤0.01% 2400

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

MetLife Investment Management's NBIX Position: Q2 2026 in Review

MetLife Investment Management reduced its Neurocrine Biosciences (NBIX) stake by 2.5% in Q2 2026, selling an estimated $196K and leaving 51,732 shares worth $8.72M. The position accounts for 0.04% of the portfolio, ranked #417.

MetLife Investment Management first reported a position in NBIX in Q3 2018 and has held it in 25 quarters since. 781 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • MetLife Investment Management held 51,732 shares of Neurocrine Biosciences worth $8.72M as of Q2 2026.
  • MetLife Investment Management sold 1,321 Neurocrine Biosciences shares in Q2 2026, an estimated $196K.
  • Neurocrine Biosciences made up 0.04% of MetLife Investment Management's portfolio in Q2 2026, its #417 holding.
  • MetLife Investment Management first reported a position in Neurocrine Biosciences in Q3 2018 and has held it in 25 quarters since.
  • 781 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.